235 related articles for article (PubMed ID: 37422840)
1. High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany.
Makhmudova U; Schatz U; Perakakis N; Kassner U; Schumann F; Axthelm C; Stürzebecher P; Sinning DL; Doevelaar A; Rohn B; Westhoff T; Vogt A; Scholl M; Kästner U; Geiling JA; Stach K; Mensch J; Lorenz E; Paitazoglou C; Eitel I; Baessler A; Steinhagen-Thiessen E; Koenig W; Schulze PC; Landmesser U; Laufs U; Weingärtner O;
Clin Res Cardiol; 2023 Nov; 112(11):1639-1649. PubMed ID: 37422840
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
Raal F; Durst R; Bi R; Talloczy Z; Maheux P; Lesogor A; Kastelein JJP;
Circulation; 2024 Jan; 149(5):354-362. PubMed ID: 37850379
[TBL] [Abstract][Full Text] [Related]
3. Inclisiran: A Review in Hypercholesterolemia.
Frampton JE
Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
[TBL] [Abstract][Full Text] [Related]
4. First clinical experiences with inclisiran in a real-world setting.
Mulder JWCM; Galema-Boers AMH; Roeters van Lennep JE
J Clin Lipidol; 2023; 17(6):818-827. PubMed ID: 37775462
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial.
Ray KK; Troquay RPT; Visseren FLJ; Leiter LA; Scott Wright R; Vikarunnessa S; Talloczy Z; Zang X; Maheux P; Lesogor A; Landmesser U
Lancet Diabetes Endocrinol; 2023 Feb; 11(2):109-119. PubMed ID: 36620965
[TBL] [Abstract][Full Text] [Related]
6. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ
N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389
[TBL] [Abstract][Full Text] [Related]
7. The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions.
Lehoux D; Kallend D; Wijngaard PLJ; Brown AP; Zerler B
Pharmacol Res Perspect; 2023 Apr; 11(2):e01080. PubMed ID: 37021909
[TBL] [Abstract][Full Text] [Related]
8. The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia.
Luo Z; Huang Z; Sun F; Guo F; Wang Y; Kao S; Yang G; Huang J; Li J; Zhao S; He Y
J Clin Lipidol; 2023; 17(3):392-400. PubMed ID: 37164838
[TBL] [Abstract][Full Text] [Related]
9. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
Ray KK; Wright RS; Kallend D; Koenig W; Leiter LA; Raal FJ; Bisch JA; Richardson T; Jaros M; Wijngaard PLJ; Kastelein JJP;
N Engl J Med; 2020 Apr; 382(16):1507-1519. PubMed ID: 32187462
[TBL] [Abstract][Full Text] [Related]
10. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
11. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease.
Nishikido T
Cardiovasc Diabetol; 2023 Jan; 22(1):20. PubMed ID: 36717882
[TBL] [Abstract][Full Text] [Related]
12. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol.
Samuel E; Watford M; Egolum UO; Ombengi DN; Ling H; Cates DW
Ann Pharmacother; 2023 Mar; 57(3):317-324. PubMed ID: 35775133
[TBL] [Abstract][Full Text] [Related]
13. Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction.
Smith KW; White CM
J Clin Pharmacol; 2022 Sep; 62(9):1079-1085. PubMed ID: 35279835
[TBL] [Abstract][Full Text] [Related]
14. Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus.
Rakocevic J; Dobric M; Vucic R; Furtula M; Zaletel I; Milutinovic K; Ilijevski A; Borovic ML; Tomasevic M; Bajcetic M
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983086
[TBL] [Abstract][Full Text] [Related]
15. [Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].
Scheen AJ; Wallemacq C; Lancellotti P
Rev Med Liege; 2022 Dec; 77(12):745-751. PubMed ID: 36484754
[TBL] [Abstract][Full Text] [Related]
16. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP;
J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis of tolerability, cardiac safety and efficacy of inclisiran for the therapy of hyperlipidemic patients.
Dutta S; Shah R; Singhal S; Singh S; Piparva K; Katoch CDS
Expert Opin Drug Saf; 2024 Feb; 23(2):187-198. PubMed ID: 38063346
[TBL] [Abstract][Full Text] [Related]
18. Small interfering ribonucleic acid for cholesterol lowering - Inclisiran: Inclisiran for cholesterol lowering.
Soffer D; Stoekenbroek R; Plakogiannis R
J Clin Lipidol; 2022; 16(5):574-582. PubMed ID: 35909047
[TBL] [Abstract][Full Text] [Related]
19. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
Fitzgerald K; White S; Borodovsky A; Bettencourt BR; Strahs A; Clausen V; Wijngaard P; Horton JD; Taubel J; Brooks A; Fernando C; Kauffman RS; Kallend D; Vaishnaw A; Simon A
N Engl J Med; 2017 Jan; 376(1):41-51. PubMed ID: 27959715
[TBL] [Abstract][Full Text] [Related]
20. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial.
Ray KK; Stoekenbroek RM; Kallend D; Nishikido T; Leiter LA; Landmesser U; Wright RS; Wijngaard PLJ; Kastelein JJP
JAMA Cardiol; 2019 Nov; 4(11):1067-1075. PubMed ID: 31553410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
